Schnider Patrick
Hoffmann-La Roche
83 Papers
592 Citations
Schnider Patrick is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Alkyl & Alkoxy group. The author has an hindex of 14, co-authored 83 publications.
Chat about Author
Papers
Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds.
TL;DR: In an analysis of recent Roche compounds, it is found that a positive charge is an important determinant for potential promiscuity; aminergic activity was found to be the main reason for overt Promiscuity.
151
Patent
4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
Michael Boes,Quirico Branca,Guido Galley,Thierry Godel,Torsten Hoffmann,Walter Hunkeler,Schnider Patrick,Heinz Stadler +7 more
- 15 Feb 2000
TL;DR: In this paper, the authors defined compounds of formula (I) wherein R is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl; R 1 is hydrogen or halogen; R 2 is a cyclic tertiary amine of the group (a).
66
Patent
4-phenyl-pyridine derivatives
Michael Bös,Quirico Branca,Guido Galley,Thierry Godel,Torsten Hoffmann,Walter Hunkeler,Schnider Patrick,Heinz Stadler +7 more
- 22 Feb 2000
TL;DR: The compounds of the related invention are related to 4-phenyl-pyridine derivatives connected by a bridge containing oxygen or nitrogen to a phenyl derivative as mentioned in this paper, which is related to the compounds of this paper.
65
Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder
Schnider Patrick,Caterina Bissantz,Andreas Bruns,Cosimo Dolente,Erwin Goetschi,Roland Jakob-Roetne,Basil Künnecke,Thomas Mueggler,Wolfgang Muster,Neil Parrott,Emmanuel Pinard,Hasane Ratni,Celine Risterucci,Mark Rogers-Evans,Markus von Kienlin,Christophe Grundschober +15 more
TL;DR: Scaffold hopping that gave rise to triazolobenzodiazepines with improved pharmacokinetic properties is described, showing the key to balancing potency and selectivity while minimizing P-gp mediated efflux was fine-tuning of hydrogen bond acceptor basicity.
48
Discovery of Highly Selective Brain-Penetrant Vasopressin 1a Antagonists for the Potential Treatment of Autism via a Chemogenomic and Scaffold Hopping Approach
Hasane Ratni,Mark Rogers-Evans,Caterina Bissantz,Christophe Grundschober,Jean-Luc Moreau,Franz Schuler,Holger Fischer,Ruben Alvarez Sanchez,Schnider Patrick +8 more
TL;DR: From a micromolar high throughput screening hit 7, the successful complementary application of a chemogenomic approach and of a scaffold hopping exercise rapidly led to a low single digit nanomolar human vasopressin 1a (hV1a) receptor antagonist suitable for human clinical studies in people with autism.
44